If approved, mivelsiran will offer a new mechanism of action for drugs used in the treatment of CAA and AD, as it will focus on reducing APP synthesis and, as a consequence, Aβ isoforms, instead of focusing on Aβ peptide/plaques clearance after they have already formed, like currently approved drugs do. Here, APP is linked to Alzheimer disease.